Mode
Text Size
Log in / Sign up
Phase 2 N=8 Treatment

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Peripheral Neuropathy · Type 1 Diabetes

Enrolled (actual)
8
Serious AEs
12.5%
Results posted
Apr 2015
Primary outcome: Primary: Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm — 6.3; 3.0; 5.2; 3.0 fibers per mm

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Salsalate (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Michigan
Primary completion
Apr 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm
6.3; 3.0; 5.2; 3.0

Summary

This 12 week study will examine the effects of daily Salsalate treatment on markers of neuropathic pain and intra-epidermal nerve fiber density. the study is being done in people with type 1 diabetes with signs and symptoms of peripheral neuropathy.

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetes (T1D)
  • Peripheral neuropathy with symptoms of pain, or with other uncomfortable symptoms (e.g., burning, prickling).
  • 18 to 70 years old
  • Stable insulin treatment program for at least the past 3 months.
  • Abnormal nerve conduction studies (based on study screening examination)
  • Willing and able to take an oral (by mouth) medication 3 times per day for 3 months.
  • WOMEN using an appropriate method of contraception during the course of the study (hormonal, IUD, or diaphragm.
  • Willing and able to provide written informed consent for study participation.

Exclusion Criteria

  • Neuropathy from a cause other than diabetes.
  • Allergy to salsalate or similar medications (aspirin, non-steroidal anti-inflammatory medicines like ibuprofen and naproxen).
  • Currently on blood thinning agents such as Coumadin, Heparin, Plavix, Pradaxa, high-dose aspirin (more than 325 mg daily).
  • Any severe low blood sugar episodes in the past 6 months (needed assistance to treat).
  • Diabetic ketoacidosis in the past 6 months.
  • Severe neuropathy, or have had an ulcer or amputation on either foot or either leg.
  • Creatinine level (a measure of kidney function is greater than 1.4 mg/dl (for women) or greater than 1.5 mg/dl (for men) or your estimated GFR is under 60.
  • Albumin in your urine or other signs of reduced kidney function.
  • Liver enzymes (including ALT, AST and Bilirubin) levels are more than 2 and ½ times the upper limit of normal.
  • Blood platelets are less than 100, 000 at the time of screening.
  • Organ transplant (lung, kidney, heart, pancreas, liver).
  • Chronic immunosuppressive therapy, for example, daily prednisone or other steroids, methotrexate, Imuran, CellCept. This includes daily, or recurrent use of oral steroids used to treat asthma.
  • Regular NSAID medications (e.g., Naproxen, Ibuprofen) use. If used occasionally, you will be asked to not use them during the study.
  • History of drug or alcohol abuse, or if you take more than 10 alcoholic drinks per week.
  • History of stomach ulcers or bleeding from your bowel.
  • Heart attack, heart bypass surgery, heart failure or a stroke EVER.
  • Current treatment for any cancer (other than basal cell or squamous cell skin cancer).
  • Treatment with lithium.
  • Ever had Reyes' syndrome.
  • Pregnant, nursing, or planning to become pregnant during the time of the study.
  • Allergic to lidocaine or epinephrine (used for numbing skin prior to biopsies).
  • Keloid scarring in the past.
  • Receiving other experimental treatments.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01480297). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search